Ageing, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity – catalysts of autoimmunity and chronic inflammation by Goronzy, Jörg J & Weyand, Cornelia M
225
ACS = acute coronary syndromes; CAD = coronary artery disease; IFN = interferon; IL = interleukin; KIR = killer immunoglobulin-like receptor;
MHC = major histocompatibility complex; NK = natural killer; RA = rheumatoid arthritis; TCR = T-cell receptor; TREC = TCR excision circle.
Available online http://arthritis-research.com/content/5/5/225
Introduction
During thymic development, large arrays of clonally distrib-
uted α–β TCRs are generated that mediate the recognition
of foreign peptides in the context of the appropriate MHC
molecule. The theoretical diversity of the TCR repertoire is
between 1015 and 1018 TCRs [1]. Thymic selection mech-
anisms impose significant restrictions on this diversity [2];
however, the resulting functional TCR repertoire is still
extensive. Arstila and colleagues [3] have estimated that
the functional T-cell repertoire in the human adult is com-
posed of >2×106 different TCR β-chains, each of which
may combine with >100 TCR α-chains. Wagner and col-
leagues [4] established even higher estimates of 2×107
different TCR β-chains in the naive T-cell compartment of
young human adults. Given that the human body harbors
~1011 T cells, these estimates imply that each naive T cell
has a clonal size of 100–1000 cells (Table 1).
Studies using the frequency of TCR excision circle
(TREC)-positive T cells as an indirect measure of diversity
are consistent with the higher estimates of diversity [5–7].
TRECs are generated during TCR rearrangement, are not
replicated, and are diluted during subsequent cell divi-
sions [8,9]. The frequency of TREC+ cells within the naive
T-cell compartment can, therefore, be taken as an indirect
measure of clonal size. Studies have suggested that this
clonal size is strictly regulated at 10–20 cells per clono-
type in the newborn and that it then slowly but steadily
increases with age [7]. Compared with the naive popula-
tion of T cells, the memory compartment is clearly con-
tracted in diversity. However, even memory T cells are very
diverse. Estimates of diversity within the memory compart-
ment range from 1×105 to 1×106 different TCR
β-chains, each combined with one or very few different
TCR α-chains [3,4].
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Abstract
Rheumatoid arthritis (RA), like many other autoimmune syndromes, is a disease of adults, with the
highest incidence rates reported in the elderly. The immune system undergoes profound changes with
advancing age that are beginning to be understood and that need to be incorporated into the
pathogenetic models of RA. The age-related decline in thymic function causes extensive remodeling of
the T-cell system. Age-dependent changes in T-cell homeostasis are accelerated in patients with RA.
The repertoire of naive and memory T cells is less diverse, possibly as a result of thymic insufficiency,
and it is biased towards autoreactive cells. Presenescent T cells emerge that are resistant to apoptosis
and that often expand to large clonal populations. These cells are under the regulatory control of
nonconventional costimulatory molecules, display potent effector functions, and appear to be critical in
the synovial and extra-articular manifestations of RA.
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It is generally assumed that this high degree of TCR diver-
sity is necessary to guarantee recognition of the universe
of antigenic peptides. In fact, the T-cell repertoire is
capable of responding to virtually any foreign organism. In
spite of its structural diversity, however, the repertoire of
functional TCR is still greatly outnumbered by potential
antigenic peptides, particularly in small mammals such as
the mouse. Plasticity in the TCR–peptide–MHC complex
may account for the recognition of multiple antigenic pep-
tides by the same TCR [10,11].
T-cell diversity, tolerance, and autoimmunity
Recent studies have interpreted the need for repertoire
diversity within the T-cell compartment from a totally differ-
ent perspective, namely, one of regulation of immune
responsiveness [12,13]. The immune system is under
strict homeostatic control [14,15]. T-cell responses to
self-antigens are prevented in the majority of individuals.
Also, the magnitude of T-cell responses to foreign anti-
gens is regulated. Generally accepted control mecha-
nisms include the induction of apoptosis in the responding
T-cell population, and feedback control by inhibitory
receptors and regulatory T cells. Remarkably, diversity of
the repertoire of naive and memory T cells has now been
established as a major additional way to control unwanted
clonal expansions, presumably functioning by means of
clonal competition for space and resources.
A characteristic example of a breakdown in this control
mechanism is the lymphopenic mouse [16–20]. Thymec-
tomy shortly after birth is generally sufficient to induce an
autoimmune syndrome. Similarly, adoptive transfer of small
numbers of naive T cells into a T-cell-deficient host
induces a wasting disease that has many features of the
autoimmune disease, inflammatory bowel disorder. These
autoimmune phenomena have been initially attributed to
the absence of regulatory cells in the thymectomized
mouse or in the lymphopenic host [16]. Experiments by
Barthlott and colleagues [12], however, have shown that
these autoimmune manifestations can be prevented by
naive T cells that lack any features of regulatory cells but
that have the potential of homeostatic expansion. Clonal
competition is in part antigen specific, and clonal T-cell
populations can selectively inhibit the division of T cells of
their own specificity [21]. Equally important, regulatory
control can also be exerted by T-cell populations of com-
pletely unrelated specificities, so long as these popula-
tions have the propensity for homeostatic proliferation
[12]. These studies emphasize the intrinsic regulatory
mechanism that is inherent in a diverse population of
T cells and that keeps autoreactive T-cell responses in
check while not curtailing immune responses to exoge-
nous antigens.
Threats to T-cell diversity
T-cell diversity is continuously challenged [2]. Antigenic
stimulation induces rapid expansion of antigen-specific
T cells that expand to large clonal sizes. This expansion is
counterbalanced by subsequent clonal contraction, which
appears to be preprogrammed. Clonal contraction is
robust and is usually sufficient to maintain a diverse
memory T-cell compartment. However, clonal T-cell popu-
lations can emerge, and they have been associated with
chronic infection such as cytomegalovirus or HIV [22].
These clonal expansions are usually limited to the memory
T-cell compartment and do not affect the diversity of naive
T cells because naive and memory T cells underlie differ-
ent homeostatic control mechanisms and compete for dif-
ferent resources [14].
One additional biological variable that has a profound
impact on T-cell homeostasis is age. The generation of
Table 1
Parameters of T-cell homeostasis in humans
T-cell population
CD4+ naive CD4+ memory CD8+ naive* CD8+ memory*
Pool size (n) ~1×10 11 ~1×10 11 ~5×10 10 ~5×10 10
Diversity (2–20)×106 TCR β-chains, each (2–20)×105 TCR β-chains, each Not determined Not determined
paired with >25 α-chains [3,4]† paired with 1–2 α-chains [3,4]†
Oligoclonality None Infrequent None Frequent in the elderly
Frequency of Ki67+ T cells (%) ~0.2 1-2 ~0.3 ~3
Daily replacement rate ~0.1 [25] ~0.8 [87] ~0.1 [25] ~0.9 [87]
by stable isotope labeling of DNA (%)
Half-life (days) ~700 ~80 ~700 ~70
Daily production rates (n) 1.5×10 8 1.5×10 9 0.8×10 8 0.8×10 9
* Phenotypic distinction imperfect.
† Data from [3] for total T cells.227
new T cells in the thymus is highest in the newborn and
then progressively declines [23]. Thymic involution pro-
gresses at the rate of ~3% per year, and individuals older
than 50 years have <15% of their thymic tissue remaining
[24]. However, the demand for production of new T cells
remains high in the adult.
In studies using endogenous labeling of DNA, the daily
fractional replacement rate is 0.1–0.6% for naive T cells,
and memory T cells turn over at a daily rate of 0.9–3.1%
[25]. In essence, adults need to produce 1.5×108 naive
T cells and 1.5×109 memory T cells every day (Table 1).
New naive T cells are only produced in the thymus. There-
fore, the formation of new T cells declines sharply with age.
The frequency of TREC+ cells, which gives an upper esti-
mate of all (intrathymic and extrathymic) newly generated
T cells, declines by >95% between the ages of 20 and
60 years. This decline demonstrates that thymic production
in a 60-year old is, at most, 5% of the capacity that existed
at the age of 20 years [5,26]. Consequently, the need for
the replenishment of naive T cells must come from the
autoproliferation of existing T cells [27]. Homeostatic prolif-
eration of naive T cells is dependent on the recognition of
self-antigen [28–30]. As a result, the generation of ‘new’
naive T cells by autoproliferation is under selective pres-
sure and ultimately leads to TCR diversity contraction.
Studies on the impact of age on the repertoire diversity of
naive T cells are not available; however, the continuous
decline in the frequency of TREC+ cells indicates a steady
increase in the average clonal size. Preliminary evidence
suggests that the contraction accelerates markedly at
approximately age 65 years, after which 95% of the CD4+
T-cell diversity is lost (unpublished observations). Data for
CD8+ naive and memory T cells are not available because
of the lack of a reliable phenotypic marker to distinguish
these subsets.
The mechanisms underlying this accelerated contraction
are unknown. Uneven homeostatic proliferation, which
favors CD4+ T cells with higher avidity for self-antigens,
may be one factor. An additional factor may be increasing
competitive pressure from memory cells and a breakdown
of distinct naive and memory cell compartments. Also, the
phenotypic distinction of naive and memory cells based on
CD45 isoforms, which is relatively reliable for CD4+
T cells, may be less distinct with age. The observed reper-
toire contraction may, in part, represent a shrinkage in size
of the naive compartment.
Contraction in diversity and dominance of clonal T-cell
populations is a relatively common finding in the memory
compartment of elderly healthy individuals [31–33]. These
clonal expansions predominantly involve CD8+ T cells, but
they can also be found in CD4+ T cells [33,34]. These
clonal expansions appear to resemble T-cell oligoclonality
that is associated with chronic infections. Indeed, clonally
expanded CD8+ T cells in otherwise healthy individuals
may be specific for cytomegalovirus [22].
T-cell diversity in rheumatoid arthritis
Early evidence that T-cell homeostasis is not intact in
patients with rheumatoid arthritis (RA) came from the
observation that these patients carried large clonally
expanded populations of CD4+ and CD8+ T cells
[35–37]. TCR studies demonstrated some degree of pref-
erence for certain TCR variable region β-chains [38,39].
However, sharing of the third complementary determining
region of the TCRs among different patients was not
found, suggesting that these T cells were not specific for a
common antigen. Also, the expanded T-cell clones were
present in the circulation as well as in inflamed tissues.
Frequencies of expanded clonotypes were independent of
disease activity and were stable over time, again suggest-
ing that these clonal expansions were not simply a conse-
quence of an antigen-driven activation event in the
synovial tissue [40].
Studies by Wagner and colleagues [4] and by Koetz and
colleagues [26] examined whether the clonal expansions
were indicators of a more profound defect in T-cell
homeostasis (Fig.1). Specifically, these authors examined
whether repertoire contraction also involved the naive
T-cell compartment. Koetz and colleagues [26] stated that
the frequency of TREC+ T cells was significantly lower in
patients with RA compared with age-matched controls.
One possible interpretation of these data is that patients
with RA have a premature diminution of thymic production.
In this model, the immune system in patients with RA
would be prematurely aged by 20–30 years and would
increasingly rely on autoproliferation to fill the void.
de Boer and colleagues [9] proposed an alternative
model; namely, these findings may be the consequence of
a primary increase in the turnover of naive T cells that
would result in dilution of TREC+ T cells. The time of
increased turnover must have preceded the onset of RA.
By the time the patients have developed RA, they have
reached a steady state as indicated by two observations.
First, the frequency of cycling Ki-67+ T cells in the periph-
eral blood of patients with RA is not increased, but is even
slightly decreased, indicating a reduced peripheral
turnover. The second observation is that the concentra-
tions of TREC+ cells are already reduced in 20-year old
patients with RA, and the subsequent age-dependent
annual loss is not different from age-matched healthy con-
trols. This again suggests that the turnover at the time of
disease is not increased [26]. Ponchel and colleagues
[41] have confirmed the reduction in TREC+ T cells in
patients with RA, and have correlated this with phenotypic
changes of naive T cells that may be the consequences of
increased homeostatic proliferation.
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Irrespective of the primary defect, these data suggest that
patients with RA have a history of increased homeostatic
proliferation of naive T cells that predated their disease,
that may have occurred to compensate for a lymphopenic
state, and that has imposed major phenotypic changes.
Increased homeostatic proliferation should lead to reper-
toire contraction and to signs of replicative stress; indeed,
this is the case.
The history of replicative stress can be assessed by mea-
suring the telomere length. Telomeres in CD4+ T cells in
healthy individuals are relatively intact until the age of
40 years, when they begin to progressively erode until
they plateau at a rather short length at the age of 65 years
[26,42]. In contrast, patients with RA have nearly com-
plete erosion of their telomeric ends in their early twenties.
Most notably, the telomeric erosion in patients with RA
affects naive T cells as well as memory T cells. Memory
T cells in healthy individuals have lost ~1000 base pairs in
telomeric length compared with naive T cells, which is
consistent with an increased replicative history of more
than 20 generations. In contrast, the telomeric lengths of
naive T cells from patients with RA are only slightly longer
than those of their own memory cells, and these telomeres
are as short as those in memory cells of healthy age-
matched individuals.
This increased replicative history is associated with a sig-
nificant contraction in TCR diversity [4]. A contraction in
diversity is to be expected if T-cell loss from the naive
compartment is compensated by homeostatic prolifera-
tion, and this is further accelerated if homeostatic prolifer-
ation is not random. Diversity of the TCR was estimated by
determining the frequency of arbitrarily selected TCR
β-chain sequences derived from either CD45RO– (naive)
or CD45RO+ (memory) CD4+ T cells. Compared with
age-matched controls, the diversity of TCR β-chains was
contracted approximately 10-fold (median frequency of a
TCR β-chain of 2×10–6 compared with 2×10–7 in con-
trols). The naive T-cell compartment, which is the primary
contributor to TCR diversity, was affected in addition to
the memory T cells. Contraction of diversity in the naive
T-cell compartment could not be attributed to contamina-
tion of memory cells that reverted to the CD45RA pheno-
type. Based on sequence analysis, the distinction
between naive CD4+ T cells and memory CD4+ T cells
was maintained. The impact of a relative lymphopenia with
subsequent increased homeostatic proliferation and reper-
toire contraction in RA is unclear but, in light of the experi-
ments in the lymphopenic mouse, it is tempting to
speculate that this scenario represents a major risk factor
for breaking tolerance and developing autoimmune dis-
eases such as RA.
Cellular T-cell senescence: a gain and loss in
function
The immune system is a highly proliferative system
because of homeostatic proliferation as well as antigen-
specific responses. It is not surprising that, with advancing
Arthritis Research & Therapy    Vol 5 No 5 Goronzy and Weyand
Figure 1
Replicative stress and contraction of TCR diversity. (a) With normal
aging, peripheral T cells develop progressive telomeric erosion as
evidence of replicative stress. (b) Frequencies of TCR excision circle
(TREC)-positive T cells decline as a consequence of thymic
dysfunction and cumulative peripheral turnover. Both processes are
accelerated in patients with rheumatoid arthritis (RA). (c) The TCR
repertoire of naive T cells in RA (light-shaded area) is markedly
contracted compared with age-matched controls (dark-shaded area).
Individual naive T cells in RA are present at higher frequencies and are
of larger clonal sizes, resulting in a lower number of different TCRs. bp,
base pairs.229
age, the immune system has evidence of high replicative
stress. Multicellular organisms have evolved a mechanism
to prevent the dysregulated growth and transformation of
proliferating cells. One such mechanism, cellular senes-
cence, was first described as a process that limits the pro-
liferation of senescent fibroblasts.
Based on these studies, three cardinal features of cellular
senescence have been defined [43]. The first is that, after
repeated divisions, the proliferative capacity of a cell starts
to dwindle and eventually ceases. One reason for this pro-
liferative arrest is the shortening of telomeres. T cells have
the ability to upregulate telomerase and they are able to
prolong their lifespan; however, they are not resistant to
telomere erosion. The second cardinal feature is that
senescent cells develop resistance to apoptotic cell death.
Finally, senescent cells undergo multiple phenotypic and
functional changes. Notably, these changes are not neces-
sarily a consequence of loss of gene expression, but they
are frequently associated with a gain in function, such as
the production of inflammatory cytokines in senescent
fibroblasts. This latter finding has led to a model of senes-
cence, the evolutionary theory of antagonistic pleiotropy
[44]. This model implies that genes selected to enhance
the fitness of young organisms have unselected deleterious
effects in the aged organism if aberrantly expressed.
Consistent with this model, replicatively stressed CD4+
and CD8+ T cells undergo multiple phenotypic and func-
tional changes (Fig.2) [45]. The most widely acknowl-
edged phenotypic change is the loss of CD28, which
increases in frequency in the CD8+ T-cell population with
age but which also occurs in CD4+ T cells to a lesser
degree [46–48]. CD28 expression is regulated at the level
of a CD28-specific initiator complex that includes the
nuclear proteins nucleolin and hnRPD [49,50]. Replicative
senescence and chronic exposure to tumor necrosis
factor alpha induce a loss of this initiator complex, particu-
larly in CD8+ T cells [51]. This loss is partially reversible by
IL-12 [52]. However, CD28 loss is not the only, and possi-
bly not the most prominent, change in gene expression in
senescent T cells. Senescent CD4+ and CD8+ T cells
acquire the expression of many genes that are generally
expressed on natural killer (NK) cells and that are associ-
ated with effector functions [53]. Even CD4+ T cells can
acquire cytotoxic activity through the expression of per-
forin and granzymes [54,55]. Also, senescent CD4+
T cells express a number of new regulatory molecules
instead of the traditional ones, such as CD28 and
CTLA-4, that control their activation or inhibition.
In particular, CD4+CD28null T cells express immunorecep-
tors of the killer immunoglobulin-like receptor (KIR) family
[53,56–58]. This receptor family is usually expressed on
NK cells and often displays specificity for MHC class I
molecules. The family is highly polymorphic, and individu-
als differ in the number of genes as well as allelic polymor-
phisms. The KIR family includes stimulatory and inhibitory
members. The stimulatory receptors require an adapter
molecule (DAP12) to be functional, but they then consti-
tute an independent recognition unit. T cells lack this
adapter molecule, and KIRs expressed on T cells are not
stimulatory on their own. However, the KIRs are able to
provide a costimulatory signal for T-cell effector functions
in the absence of DAP12 [59]. This costimulatory signal
functions through the activation of the c-Jun N-terminal
kinase pathway, and it is important in lowering the thresh-
old in response to TCR stimulation.
In essence, the aging T-cell compartment is characterized
by the increased frequency of highly competent effector
T cells that are under the control of regulatory molecules
found on NK cells. It can be envisioned, based on their
unique properties, that these T-cell populations play an
important role in tissue injury and in loss of self-tolerance
as the biological system ages.
Senescent T cells: facilitators of inflammation
Expansion of CD4+ and CD8+ T cells that have lost the
expression of CD28, and are presumably senescent, has
been observed in several autoimmune diseases including
diabetes mellitus, RA, Wegener’s granulomatosis, multiple
sclerosis, and ankylosing spondylitis [60–64]. In general,
these cells were clonally expanded and included autoreac-
tive T cells, implicating them directly in the pathogenesis
of these diseases. In RA, specifically, increased frequen-
cies of CD4+CD28null T cells are associated with more
severe disease, again providing evidence for a direct role
of these cells in the disease manifestations. In early RA,
the frequency of CD4+CD28null T cells is a predictor for
erosive progression [65]. In the established disease, the
frequency correlates with extra-articular manifestations
[66]. Increased frequencies are seen in nodular disease,
and the highest frequencies are found in patients with
rheumatoid vasculitis. Also, the T-cell type of large granu-
lar lymphocytes seen in Felty-like conditions appears to be
directly related to the senescent CD28null T cells [67].
At first sight, the loss of CD28 would suggest that these
cells are functionally anergic and prone to apoptosis;
however, the opposite is the case. These cells are very
potent effector cells, and at least CD4+CD28null T cells
are resistant to apoptosis (the data on CD8+ T cells are
contradictory) [68–70]. Resistance to apoptosis-inducing
signals cannot be attributed to a single mechanism but is
acquired and multifactorial, consistent with the senescent
phenotype of these cells. CD4+CD28null T cells express
more bcl-2, which renders them less sensitive to growth-
factor withdrawal [68]. CD4+CD28null T cells are also
resistant to Fas-mediated apoptosis. These cells fail to
degrade FLIP following T-cell activation and/or IL-2 stimu-
lation. They, therefore, do not activate the death pathway
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upon Fas-ligand engagement [69]. The resistance to
growth-factor withdrawal and Fas signaling may prevent
the usual clonal downsizing in vivo after antigen-specific
stimulation.
The accumulation of oligoclonal T-cell populations appears
to be more the consequence of a prolonged survival than
increased proliferation, again consistent with the concept
of cellular senescence. Given the central role of T-cell
apoptosis in T-cell homeostasis and peripheral tolerance,
the prolonged survival of these cells may contribute to their
role in inflammatory diseases. Specifically, overexpression
of c-FLIP has been shown to induce autoimmunity [71].
In addition to resistance to apoptosis, other functional and
phenotypic changes in senescent T cells in RA are of
importance for their role in perpetuating chronic tissue
inflammation. First, the shift in regulatory molecules, from
the classic CD28–CD80/CD86 pathway to alternate
immunoreceptors, changes the cellular context in which
T-cell stimulation is facilitated. There is no longer a unique
role for professional antigen-presenting cells that express
CD80/CD86, but other cell types can be T-cell stimula-
tory. More importantly, CD4+CD28null T cells are very
potent effector T cells and can cause tissue injury by virtue
of their high cytotoxic activity and their excessive produc-
tion of proinflammatory cytokines, including tumor necro-
sis factor alpha and IFN-γ. There is evidence that both
dimensions are of functional importance in RA. Weissman
and colleagues [72] were the first to postulate a role for
perforin/granzyme-positive CD4+ T cells in the synovial
inflammation of patients with RA, and also in one patient
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Figure 2
Replicative senescence and shifts in gene expression. Cumulative replication of T cells is associated with telomeric erosion and loss of CD28 and
CD40L expression, consistent with cellular senescence. Presenescent CD4+ T cells gain effector functions such as high production of cytokines
and cytotoxic ability through a perforin/granzyme mechanism. These cells are under the regulatory control of MHC class I-recognizing receptors,
such as killer immunoglobulin-like receptors (KIRs), that can provide costimulatory signals or, if coexpressed with the appropriate adapter molecule
DAP12, form an independent, fully competent recognition unit.231
with ankylosing spondylitis. Namekawa and colleagues
[54] demonstrated the presence of these cells in the syn-
ovial tissue of patients with RA, again postulating that the
gain in cytotoxic function is of functional importance in
maintaining chronic synovitis.
Regulatory genes of the KIR family have been identified as
disease risk genes in RA and in psoriatic arthritis [73,74].
In patients with RA, in particular those who have extra-artic-
ular manifestations, oligoclonal T-cell populations were
found to preferentially express the stimulatory KIR2DS2
gene, often in the absence of inhibitory KIRs or inhibitory
receptors of the c-type lectin family, CD94/NKG2A [75].
Indeed, expression of KIR2DS2 had functional implications
in that it sensitized the T cells to respond to subthreshold
TCR stimulation. The KIR2DS2 gene, present in only 40%
of a healthy Caucasian population, was found in associa-
tion studies to be a risk factor for rheumatoid vasculitis
[73]. Association studies also suggested a role for the
stimulatory immune receptors, KIR2DS1 and KIR2DS2, in
the risk of developing psoriatic arthritis [74].
Senescent T cells: shifting the balance from
tissue homeostasis to tissue inflammation in
coronary artery disease
Acquisition of new functions by senescent T cells appears
not only to be important in autoimmune disease manifesta-
tions but also in more subtle inflammatory reactions that
are associated with tissue homeostasis and repair. One
characteristic example is coronary artery disease (CAD).
It is well established that activation of systemic inflamma-
tory responses, as exemplified by elevated C-reactive
protein levels, is a risk factor for adverse outcome in
patients with CAD [76]. The atherosclerotic plaque is now
understood to be an inflammatory lesion. Inflammation may
lead to plaque rupture and subsequent thrombosis, and it
may cause the clinical manifestations of acute coronary
syndromes (ACS) such as myocardial infarction and
unstable angina [77–79]. Patients with ACS have highly
elevated frequencies of CD4+CD28null T cells, consistent
with the notion that they have a pre-aged immune system
[80]. CD4+CD28null T cells have been isolated from rup-
tured coronary plaques that have caused fatal myocardial
infarction or have been isolated from plaque material that
was harvested during angioplasty of unstable plaques
[81]. CD4+CD28null T cells from patients with ACS
produce large amounts of IFN-γ in vitro [82], and
increased IFN-γ activity  in vivo can be demonstrated.
IFN-γ-inducible genes are upregulated in the peripheral
blood of patients with ACS, and circulating monocytes
show evidence of nuclear translocation of STAT-1 homod-
imers, indicative of IFN-γ receptor triggering.
CD4+CD28null T cells are also cytotoxic towards endothe-
lial cells, and this activity can be significantly enhanced by
C-reactive protein [83].
Taking the data together, CD4+CD28null T cells appear to
be instrumental in plaque rupture, either indirectly via
IFN-γ-mediated activation of macrophages or directly via
their cytotoxic activity. Again, as seen in patients with RA,
the activity of CD4+CD28null T cells can be modulated by
regulatory receptors of the KIR family [84]. CD4+ T cells
frequently express KIRs, specifically stimulatory isoforms,
in patients with ACS. Most interestingly, T cells in patients
with ACS can also express the adaptor molecule, DAP12.
The coexpression of DAP12 and the stimulatory receptor
encoded by the KIR2DS2 gene is sufficient to form an
independent antigen recognition unit that confers the
ability to fully activate a T cell, even in the absence of TCR
triggering. Such activation potential in T cells should have
detrimental consequences for maintaining tolerance and
tissue integrity, a characteristic example being the plaque
rupture in a coronary artery lesion.
Sharing of immunosenescent mechanisms between ACS
and RA provides a pathogenic framework for the recent
clinical observations that the increased mortality of
patients with RA can be attributed to coronary atheroscle-
rosis and its complications [85]. In a case–control study,
patients with RA were more likely to have multivessel coro-
nary involvement at the first coronary angiogram compared
with the general population (KJ Warrington, PD Kent, RL
Frye, JF Lymp, SL Kopecky, JJ Goronzy, CM Weyand,
manuscript submitted). The risk for accelerated CAD con-
ferred by RA remained significant after adjustment for tra-
ditional risk factors. This example also illustrates how the
distinction between the autoreactive response leading to
autoimmune disease and the local inflammatory response
of tissue repair can be blurred. The same mechanism, in
this case immunosenescence, is responsible for the
chronic destructive inflammatory disease itself as well as
for its seemingly unrelated comorbidities.
Conclusion
RA is a disease that predominantly occurs in adults and
has its highest incidence rates in the elderly [86]. This
coincides with a period when the generation of new
T cells is minimal and the ability to mount a naive T-cell
response to new exogenous antigens starts to decline or
is already severely compromised. Studies in patients with
RA have shown that immune aging is accelerated, raising
the question of whether the breakdown in tolerance can
be truly explained within the classic models of an auto-
reactive T-cell response to a disease-inducing antigen or
whether age-dependent changes of the immune system
represent a critical factor.
The repertoire of naive T cells in RA is contracted and
shows evidence of senescence, which may predispose
the system to autoimmune responses that mirror the
mechanisms in the lymphopenic mouse. In RA, presenes-
cent memory T cells emerge that have acquired many
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functions of NK cells and are proinflammatory cells. We
propose that the distinction between self and nonself
requires a functional and competent immune system. Age-
related degeneration of immunocompetence imposes an
immediate risk on the complex processes of self-tolerance
(Fig.3). With premature immune aging in RA, failure of
self-tolerance may occur more easily and earlier in life.
Effector functions of presenescent T cells are critical for
the autoimmune manifestations of RA, including some of
the comorbidities of RA, such as CAD.
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Figure 3
Pathomechanisms in rheumatoid arthritis. The diagram illustrates how aging, altered T-cell homeostasis, and cellular senescence may be
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